[{"Assets_0_Q2_USD":261630000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":48573000.0,"NetIncomeLoss_2_Q2_USD":15698000.0,"NetIncomeLoss_1_Q2_USD":6725000.0,"StockholdersEquity_0_Q2_USD":172481000.0,"EarningsPerShareBasic_1_Q2_USD":0.49,"EarningsPerShareBasic_2_Q2_USD":1.13,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":13853580.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":13782720.0,"Ticker":"EGRX","CIK":"827871","name":"EAGLE PHARMACEUTICALS, INC.","OfficialName":"Eagle Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20190630","fy":"2019.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"635235963.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20190808"}]